Results 31 to 40 of about 20,923 (159)
iScience, 2023 Summary: Obesity has become a global epidemic, associated with several chronic complications. The intestinal microbiome is a critical regulator of metabolic homeostasis and obesity.
Junfeng Shi +10 more
doaj +1 more source
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. [PDF]
PLoS ONE, 2017 Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease.
David Cherney +5 more
doaj +1 more source
Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
, 2015 Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (
Andrew Ahmann
core +1 more source
Empagliflozin in Patients with Chronic Kidney Disease [PDF]
, 2023 This article relates to a research study that included patients or members of the workforce as study participants from GP practices in Nottingham and Nottinghamshire.Background: The effects of empagliflozin in patients with chronic kidney disease who are
The EMPA-KIDNEY Collaborative Group
core +2 more sources
Clinician’s guide for empagliflozin use in heart failure [PDF]
, 2022 Empagliflozin belongs to the new class of drugs for the treatment of heart failure, sodium-glucose co-transporter type 2 inhibitors. Results of the EMPEROR-Reduced, EMPEROR-Preserved and EMPULSE trials confirmed the clinical benefits of empagliflozin ...
Lelonek, Małgorzata; Department of Noninvasive Cardiology, Medical University of Lodz, Łódź, Poland
core +1 more source
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Biomedicines, 2022 Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD.
Silvie Hojná +8 more
doaj +1 more source
Stability Indicating Assay of Empagliflozin and Linagliptin [PDF]
, 2023 The newly developed stability‐indicating RP-HPLC method is simple, robust, and validated on the basis of ICH guidelines for simultaneous determination of Empagliflozin and Linagliptin in tablets.
Sudam Chandra Si, Saroja Kumar Patro, Lalit Kumar Sahu,
core +1 more source
AntioxidantsCarfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications.
Mina Y. George +3 more
doaj +1 more source
Cellular & Molecular Biology Letters, 2023 Background Renal ischemia–reperfusion injury (IRI) is one reason for renal transplantation failure. Recent studies have shown that mitochondrial dynamics is closely related to IRI, and that inhibition or reversal of mitochondrial division protects organs
Wenbo Yang +9 more
doaj +1 more source
, 2014 Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin ...
Joshua J Neumiller
core +1 more source